Skip to main content

Table 4 1-, 2-, 3-year Survival

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Survival Cohort 1 (N = 30) Cohort 2 (N = 15)
1-year 18 (60%) 8 (53%)
2-year 14 (46.7%) 6 (40%)
3-year 9 (30%) 4 (26.7%)